-+ 0.00%
-+ 0.00%
-+ 0.00%

Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

Benzinga·10/02/2026 17:53:27
語音播報
Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises the price target from $4 to $8.